{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:23:25Z","timestamp":1789457005999,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaip.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T19:17:56Z","timestamp":1737746276000},"page":"1358-1366.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Poor Agreement Among Asthma Specialists on the Choice and Timing of Initiation of a Biologic Treatment for Severe Asthma Patients"],"prefix":"10.1016","volume":"13","author":[{"given":"Andr\u00e9anne","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Beaul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c8ve","family":"Boulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakie","family":"Guertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Philippe","family":"Boulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystelle","family":"Godbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.01.017_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.01.017_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105860","article-title":"Severe asthma is related to high societal costs and decreased health related quality of life","volume":"162","author":"Jansson","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060160","article-title":"Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France","volume":"12","author":"Roche","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2025.01.017_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/JAA.S272681","article-title":"Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States","volume":"13","author":"Song","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.01.017_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106670","article-title":"A systematic literature review of burden of illness in adults with uncontrolled moderate\/severe asthma","volume":"191","author":"Czira","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib7","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.01.017_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00765-2017","article-title":"\"I have lost in every facet of my life\": the hidden burden of severe asthma","volume":"50","author":"Foster","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.01.017_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.01.017_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12931-016-0482-9","article-title":"Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study","volume":"17","author":"Loza","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2025.01.017_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2\u2013driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.01.017_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.01.017_bib17","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.01.017_bib18","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib19","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib20","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2025.01.017_bib21","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2025.01.017_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.anai.2022.01.024","article-title":"A rational approach to compare and select biologic therapeutics in asthma","volume":"128","author":"Wang","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.01.017_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaip.2021.10.059","article-title":"Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion","volume":"10","author":"Buhl","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.01.017_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaip.2017.05.015","article-title":"Severe Asthma Phenotypes\u2014how should they guide evaluation and treatment?","volume":"5","author":"Fitzpatrick","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.01.017_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113978","article-title":"Prediction of response to biological treatment with monoclonal antibodies in severe asthma","volume":"179","author":"Kroes","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaip.2025.01.017_bib29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.01.017_bib30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12874-020-01065-0","article-title":"International Severe Asthma Registry (ISAR): protocol for a global registry","volume":"20","author":"FitzGerald","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2025.01.017_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jaip.2025.01.017_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jaip.2025.01.017_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"key":"10.1016\/j.jaip.2025.01.017_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.jaip.2025.01.017_bib35","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2147\/JAA.S377174","article-title":"Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy","volume":"15","author":"Chen","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.01.017_bib36","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2025.01.017_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.01.017_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.01.017_bib40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/jpm13061020","article-title":"Clinical asthma remission obtained with biologics in real life: patients' prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.jaip.2025.01.017_bib41","first-page":"2287","article-title":"On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study","volume":"60","author":"Castro","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.01.017_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.01.017_bib43","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.01.017_bib44","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","article-title":"Global variability in administrative approval prescription criteria for biologic therapy in severe asthma","volume":"10","author":"Porsbjerg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:29:48Z","timestamp":1752578988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2213219825000613"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.01.017","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poor Agreement Among Asthma Specialists on the Choice and Timing of Initiation of a Biologic Treatment for Severe Asthma Patients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}